Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan
Matteo Bargagli(University of Bern), Daniel G. Fuster(University of Bern), Bruno Vogt(Hypertension Institute), Pietro Manuel Ferraro(Università Cattolica del Sacro Cuore), Manuel Anderegg(University of Bern), Nasser A. Dhayat(University of Bern), Mariam Semmo(University Medical Center Freiburg), Uyen Huynh‐Do(Hypertension Institute)
Cited by 34
Related Papers
CKD Prevalence Varies across the European General Population
|Journal of the American Society of Nephrology|2015|588
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Comparison of continuous and intermittent renal replacement therapy for acute renal failure
|Nephrology Dialysis Transplantation|2005|343
SLC9/NHE gene family, a plasma membrane and organellar family of Na+/H+ exchangers
|Molecular Aspects of Medicine|2013|280
Traditional and emerging roles for the SLC9 Na+/H+ exchangers
|Pflügers Archiv - European Journal of Physiology|2013|187